Labcorp rolls out FDA‑cleared pTau‑181 Alzheimer’s blood test to primary care nationwide
- Labcorp is rolling out Elecsys pTau-181 blood testing in primary care nationwide for symptomatic patients age 55+.
- Labcorp says Elecsys pTau-181 is the first FDA‑cleared blood test aiding initial Alzheimer’s assessment in primary care.
- Labcorp cites 97.9% negative predictive value to reduce specialist referrals and speed diagnostic pathways.
Primary-care access widens for Alzheimer’s biomarker testing
Labcorp is rolling out the Elecsys pTau-181 blood test into primary care settings nationwide, offering clinicians a simple in‑office blood draw for symptomatic patients aged 55 and older. Developed by Roche Diagnostics and cleared by the U.S. Food and Drug Administration in 2025, the assay is now available at physician offices and any of Labcorp’s more than 2,200 patient service centers as an alternative to brain imaging or lumbar puncture.
Labcorp brings FDA-cleared pTau-181 into primary care
The company says the Elecsys pTau-181 is the first and only FDA‑cleared blood test intended to aid initial Alzheimer’s assessment in primary care, and it is being positioned to help clinicians rule out Alzheimer’s pathology by identifying patients unlikely to have amyloid buildup. Labcorp highlights a 97.9% negative predictive value for the assay, enabling primary care teams to direct patients with negative results toward evaluation for other causes of cognitive decline and to refer those with positive results for confirmatory testing.
Labcorp frames the expansion as a practical response to workforce constraints and access barriers. With a national shortage of neurologists and roughly 7.2 million Americans living with Alzheimer’s disease, the company says wider availability of a validated blood biomarker can reduce unnecessary specialist referrals, speed diagnostic pathways and support earlier, more timely conversations about care. Dr. Brian Caveney, Labcorp’s chief medical and scientific officer, notes primary care clinicians are often the first contact for cognitive concerns and that bedside-accessible testing helps patients get answers sooner and guide next steps with greater confidence.
Broader clinical implications
Clinicians and health systems gain a low‑burden screening tool that integrates with existing primary care workflows, Labcorp says, which may lower costs and shorten time to diagnosis compared with imaging or cerebrospinal fluid testing. The company anticipates the test will be used as an initial triage step rather than a stand‑alone diagnostic, informing decisions about further biomarker testing, neuroimaging or specialist referral.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

